Tesetaxel

In this article, we will explore the fascinating world of Tesetaxel, a topic that has captured the attention and interest of people around the world. With a rich history and significant influence on different aspects of daily life, Tesetaxel has played a fundamental role in society over time. Through an in-depth analysis, we will examine the different aspects and dimensions of Tesetaxel, from its origin and evolution to its impact today. Whether you are an expert on Tesetaxel or just getting into this topic, this article will provide you with valuable information and unique perspectives that will allow you to better understand its importance and relevance in today's world.

Tesetaxel
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • (2aS,2bR,3S,4S,6S,8aR,10S,11aS,11bR,13aR)-2a-(acetyloxy)-6-{-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoyl]oxy}-10--4-hydroxy-7,11b,14,14-tetramethyl-2a,2b,3,4,5,6,8a,11a,11b,12,13,13a-dodecahydro-2H-4,8-methanodioxolocyclodecabenzoxet-3-yl benzoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC46H60FN3O13
Molar mass881.992 g·mol−1
3D model (JSmol)
  • CC1=C23(4(CC5(4((C2(C)C)(C1OC(=O)((C6=C(C=CC=N6)F)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)C)O(O3)CN(C)C
  • InChI=1S/C46H60FN3O13/c1-24-28(58-40(54)34(52)33(32-27(47)17-14-20-48-32)49-41(55)63-42(3,4)5)21-46(56)38(61-39(53)26-15-12-11-13-16-26)36-44(8,19-18-29-45(36,23-57-29)62-25(2)51)37-35(31(24)43(46,6)7)59-30(60-37)22-50(9)10/h11-17,20,28-30,33-38,52,56H,18-19,21-23H2,1-10H3,(H,49,55)/t28-,29+,30+,33-,34+,35+,36-,37+,38-,44+,45-,46+/m0/s1 ☒N
  • Key:MODVSQKJJIBWPZ-VLLPJHQWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tesetaxel is an orally administered taxane being investigated as a chemotherapy agent for various types of cancer, including breast cancer,[1] gastric cancer,[2] colorectal cancer,[3] and other solid tumors.[4] It differs from other members of the taxane class (e.g. paclitaxel or docetaxel) in that it is administered orally, not intravenously.[5]

References

  1. ^ Clinical trial number NCT01221870 for "Tesetaxel as First-line Therapy for Metastatic Breast Cancer" at ClinicalTrials.gov
  2. ^ Evans T, Dobrila R, Berardi R, Sumpter KA, Wall LR, Oyama R, Anthoney DA (June 2006). "A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen". Journal of Clinical Oncology. 24 (18_suppl): 4081. doi:10.1200/jco.2006.24.18_suppl.4081.
  3. ^ Clinical trial number NCT00080834 for "DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT01315431 for "A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors" at ClinicalTrials.gov
  5. ^ Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A (May 2003). "DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo". Cancer Science. 94 (5): 459–66. doi:10.1111/j.1349-7006.2003.tb01465.x. PMC 11160250. PMID 12824894.